Definitive Contract 75N92021C00010
Award Date 3/31/21
Potential Completion Date 1/31/25
Potential Value $16M
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bedford, NH 03110, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Mologic Inc., a foreign-owned for-profit organization located in Great Britain, was awarded a $59,010 firm fixed price purchase order by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The purchase order, which had no set-aside designation and was completed on June 3, 2020, was for custom antibody development in support of NIAID's biomedical research mission. As a leading developer of lateral flow immunoassay tests, Mologic Inc....
- This is a $6,250,000.00 firm fixed-price definitive contract awarded by the National Heart Lung and Blood Institute, a civilian agency, to Meridian Bioscience Inc., a foreign-owned, for-profit manufacturer of in vitro diagnostic test kits and medical testing technologies. The contract is for the Rapid Acceleration of Diagnostics (RADx) Tech Project #6139, which involves the supply of Meridian Bioscience's RevogeneⓇ SARS-CoV-2 assay. This diagnostic test is being procured to support the...
- The National Institutes of Health awarded a $50.7 million firm fixed price modification to MicroGEM US Inc. under the RADX Tech Program. The modification extends an existing contract to maintain MicroGEM's production of 160,000 saliva-based, high-performing RT-PCR point-of-care cartridges and 1,000 portable devices per day for COVID-19 testing. The 25-minute tests and devices are non-invasive and portable. Funding comes from the Department of Health and Human Services National Institutes of...
- The National Institutes of Health (NIH) awarded a $92,645,361.50 firm-fixed-price contract to Quidel Corporation to provide rapid COVID-19 antigen test kits under the Rapid Acceleration of Diagnostics (RADx) initiative. The contract, which does not have a set-aside designation, runs through April 30, 2025 and requires Quidel to deliver the tests from its facilities in San Diego, California. Quidel is a manufacturer of medical diagnostics and supplies, and has received numerous federal...
- This is a $24,860,014.00 firm-fixed-price contract awarded by the National Heart, Lung, and Blood Institute (NHLBI), a civilian agency, to Mesa Biotech Inc. for the development of an easy-to-use, low-cost molecular-based SARS-CoV-2 test. The contract is part of the Rapid Acceleration of Diagnostics (RADx) program, which aims to accelerate the development, validation, and commercialization of innovative COVID-19 testing technologies. The contract has a performance period ending on May 4, 2024,...
- This definitive contract awarded by the Department of Health and Human Services' National Institutes of Health National Institute of Biomedical Imaging and Bioengineering is valued at $1,462,373.11 to Ubiquitome Limited of New Zealand. Under the contract, Ubiquitome will support the RADX program's goal of accelerating diagnostic testing for SARS-CoV-2 by developing the Liberty16 mobile real-time PCR test to make accurate Covid-19 lab testing accessible to all Americans. The firm fixed price...
- This is a federal contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Detect Inc. for the Rapid Acceleration of Diagnostics (RADx) Tech II program. The contract is valued at $8,085,388.00 and has a firm fixed price pricing type. The contract is for the "Expanded Manufacturing and Commercialization of 'Detect' COVID-19 Test: Highly Scalable, Affordable, At-Home Rapid Test" project, with a completion date of October 13, 2022. This contract...
- The U.S. Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Heart Lung and Blood Institute awarded Ellume USA LLC, a foreign-owned, self-certified small disadvantaged business, a $26,900,000 firm-fixed-price contract for the development of a point-of-care COVID-19 antigen test for the direct detection of the SARS-CoV-2 virus. This contract, part of the RADX-TECH program, has a completion date of March 29, 2023 and does not have a set-aside designation....
- The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $890,386.49 firm fixed-price definitive contract to Salignostics LTD for the development of a saliva-based SARS-CoV-2 rapid diagnostic test under the Rapid Acceleration of Diagnostics (RADX) Program, Tech Project #6808. The contract, awarded on May 17, 2021, with an ultimate completion date of November 8, 2021, supports the federal government's coronavirus response efforts. Performance of the work is designated...
- The National Institute of Biomedical Imaging and Bioengineering (NIBIB), a civilian agency, awarded a $3,750,864 firm-fixed-price contract to Avantgen Inc., a San Diego-based biotechnology company, to develop a highly sensitive rapid test kit for SARS-CoV-2 that does not require a reader. This contract is part of the Rapid Acceleration of Diagnostics (RADx) program and has a completion date of September 29, 2023. The contract was not set aside for any specific business type. Avantgen has...